Diffuse Large B-Cell Lymphoma — Trials

Diffuse Large B-Cell Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

1,150 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 355
Recruiting: 190
Ph III recruiting: 16
Growth YoY: −11.6%
Industry share: 26%
Top sponsor: National Cancer Institute (NCI)
Termination share: 38.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (177)

clinicaltrialsPublishedShowing 51–75 of 75 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05755087	Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma	recruiting	Phase 1	18	Lapo AlinariOTHER	1	Feb 27, 2026	clinicaltrials
NCT04186520	CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies	recruiting	Phase 1 / Phase 2	100	Medical College of WisconsinOTHER	1	Feb 23, 2026	clinicaltrials
NCT05432635